139 related articles for article (PubMed ID: 30703267)
1. When Is a Medicine Good Enough?: Science, Similarity, and the History of Generic Drugs.
Greene JA
Clin Pharmacol Ther; 2019 Feb; 105(2):290-291. PubMed ID: 30703267
[No Abstract] [Full Text] [Related]
2. Quality of generic ophthalmic drugs.
Novack GD
Ocul Surf; 2013 Jan; 11(1):54-6. PubMed ID: 23321360
[No Abstract] [Full Text] [Related]
3. The case for standardizing the appearance of bioequivalent medications.
Engelberg AB
J Manag Care Pharm; 2011 May; 17(4):321-3. PubMed ID: 21534643
[No Abstract] [Full Text] [Related]
4. Clinical Endpoint Bioequivalence Studies Are Needed: A Perspective From Brand Drugs.
Krishna R; Kesisoglou F
Clin Pharmacol Ther; 2019 Feb; 105(2):298-300. PubMed ID: 30456848
[No Abstract] [Full Text] [Related]
5. Multinational medicines--ensuring drug quality in an era of global manufacturing.
Okie S
N Engl J Med; 2009 Aug; 361(8):737-40. PubMed ID: 19692686
[No Abstract] [Full Text] [Related]
6. History and regulatory issues of generic drugs.
Meyer GF
Transplant Proc; 1999 May; 31(3A Suppl):10S-12S. PubMed ID: 10330951
[TBL] [Abstract][Full Text] [Related]
7. Bioequivalence: the regulatory career of a pharmaceutical concept.
Carpenter D; Tobbell DA
Bull Hist Med; 2011; 85(1):93-131. PubMed ID: 21551918
[TBL] [Abstract][Full Text] [Related]
8. A brief history of generic substitution in the USA.
Sullivan CG
Pharm Pat Anal; 2012 Mar; 1(1):9-11. PubMed ID: 24236706
[No Abstract] [Full Text] [Related]
9. The substance of the brand.
Greene JA
Lancet; 2011 Jul; 378(9786):120-1. PubMed ID: 21748873
[No Abstract] [Full Text] [Related]
10. Lawsuits anticipated on generic biologicals front.
Fox JL
Nat Biotechnol; 2003 Jul; 21(7):721-2. PubMed ID: 12833078
[No Abstract] [Full Text] [Related]
11. [Generic drugs in Brazil: historical overview and legislation].
Araújo LU; Albuquerque KT; Kato KC; Silveira GS; Maciel NR; Spósito PÁ; Barcellos NM; Souza Jd; Bueno M; Storpirtis S
Rev Panam Salud Publica; 2010 Dec; 28(6):480-92. PubMed ID: 21308175
[TBL] [Abstract][Full Text] [Related]
12. Scientific and legal viability of follow-on protein drugs.
Dudzinski DM; Kesselheim AS
N Engl J Med; 2008 Feb; 358(8):843-9. PubMed ID: 18287608
[No Abstract] [Full Text] [Related]
13. Bioequivalence and interchangeability of narrow therapeutic range drugs. Canadian Society for Pharmaceutical Sciences discussion.
Palylyk-Colwell E; Jamali F; Dryden W; Friesen E; Koven S; Mohamed I; Osmond B; Alessi-Severini S; Sheldon L; Sheldon R; Tam Y; Tsuyuki R; Zhanel G
J Pharm Pharm Sci; 1998; 1(1):2-7. PubMed ID: 10942966
[No Abstract] [Full Text] [Related]
14. FDA reiterates warning against online drug buying.
Rados C
FDA Consum; 2004; 38(5):17. PubMed ID: 15595143
[No Abstract] [Full Text] [Related]
15. Generic and alternative brand-name pharmaceutical equivalents: select with caution.
Hendeles L; Hochhaus G; Kazerounian S
Am J Hosp Pharm; 1993 Feb; 50(2):323-9. PubMed ID: 8480793
[No Abstract] [Full Text] [Related]
16. Bioequivalence of oral products and the biopharmaceutics classification system: science, regulation, and public policy.
Amidon KS; Langguth P; Lennernäs H; Yu L; Amidon GL
Clin Pharmacol Ther; 2011 Sep; 90(3):467-70. PubMed ID: 21775984
[TBL] [Abstract][Full Text] [Related]
17. [A century of evolution, and revolution, in research and development of drugs].
Cadórniga Carro R
An R Acad Nac Med (Madr); 2000; 117(1):23-106. PubMed ID: 11209558
[No Abstract] [Full Text] [Related]
18. [Generics and brands in chemotherapy].
Grigor'ev VIu
Antibiot Khimioter; 2006; 51(8):38-47. PubMed ID: 18030783
[No Abstract] [Full Text] [Related]
19. Generic vs. brand name drugs--defining and enforcing standards.
Lasagna LC
Internist; 1979 May; 20(4):11, 13. PubMed ID: 10316827
[No Abstract] [Full Text] [Related]
20. The integrity of generic drugs.
Fisher DW
Hosp Pract (Off Ed); 1989 Sep; 24(9):9. PubMed ID: 2504753
[No Abstract] [Full Text] [Related]
[Next] [New Search]
